FDA Reviews Plozasiran: A Potential First-in-Class Therapy for Familial Chylomicronemia Syndrome
Plozasiran significantly reduces triglyceride levels and pancreatitis risk in FCS patients, offering hope for effective treatment options.
Arbli From Scienture
FDA approves a new liquid formulation of losartan for hypertension treatment, enhancing accessibility for adults and children over 6 years…
Pharmacists and Providers: Key Collaborators in the Shift Toward Decentralized and Virtual Health Care
Virtual health care enhances patient experiences, integrates complex data, and ensures medication access through provider-pharmacist collaboration.
New Drug Combination Shows Promise Against Resistant Influenza Strains
Researchers unveil a promising drug combination, arainosine and theobromine, that effectively targets influenza A M2 channels, outperforming existing treatments.
Semaglutide Receives FDA Approval for Treatment of MASH
FDA approves semaglutide for treating MASH, offering new hope for affected individuals.
Adapting Oncology Pharmacy to the Age of AI and Drug Shortages
Oncology pharmacists are increasingly shaping patient care.
FDA Approves Tonmya, First Treatment for Fibromyalgia in Over 15 Years
FDA approves Tonmya, the first new fibromyalgia treatment in 15 years, offering hope for effective pain relief and improved quality…
1053: The Sicker the Patient, the Worse Dexmedetomidine Performs?
Show notes at pharmacyjoe.com/episode1053. In this episode, I’ll discuss predicting the chance of successful sedation and the development of hypotension…
Selection Considerations for Abemaciclib Versus Ribociclib in Early HR+/HER2- Breast Cancer: Efficacy, Safety, and Long-Term Outcomes
New research highlights abemaciclib and ribociclib as promising treatments for early HR-positive, HER2-negative breast cancer, emphasizing survival benefits and side…